Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold, Ludwig Kappos, Douglas L. Arnold, +8

New England Journal of Medicine

JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency

Maria Chiara Monaco, Walter J. Atwood, Maneth Gravell, +2

Journal of Virology

Viral PathogenesisImmunologyPathologyHematopoietic Progenitor CellsImmune System +19

Persistent human immunodeficiency virus type 1 infection in human fetal glial cells reactivated by T-cell factor(s) or by the cytokines tumor necrosis factor alpha and interleukin-1 beta

Carlo Tornatore, Avindra Nath, Kei Amemiya, +1

Journal of Virology

ImmunologyPathologyHiv-1 GenomeHiv-1 Genome ExpressionNeuroinflammation +17

Varicella-Zoster Virus Infections in Patients Treated With Fingolimod

Ann M. Arvin, Jerry S. Wolinsky, Ludwig Kappos, +8

JAMA Neurology

Temporal patterns of human immunodeficiency virus type 1 transcripts in human fetal astrocytes

Carlo Tornatore, Karen Meyers, Walter J. Atwood, +2

Journal of Virology

ImmunologyHiv-1 LatencyNeuroinflammationHuman RetrovirusNeurology +16

Amyloid-β ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Enchi Liu, Mark E. Schmidt, Richard Margolin, +892

Neurology

Extended interval dosing of natalizumab in multiple sclerosis

Lana Zhovtis Ryerson, Teresa C. Frohman, John Foley, +25

Journal of Neurology Neurosurgery & Psychiatry

Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial

John R. Corboy, Robert J. Fox, Ilya Kister, +24

The Lancet Neurology

Disease ProgressionNeurological DisorderMedicineNew Disease ActivityClinical Trials +5

Relapsing and remitting human immunodeficiency virus—associated leukoencephalomyelopathy

Joseph R. Berger, Carlo Tornatore, Eugene O. Major, +7

Annals of Neurology

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)

Stanley Cohan, Harold Moses, Jonathan Calkwood, +9

Multiple Sclerosis and Related Disorders